From the early 1900s through the mid-2000s, the global cord blood banking industry expanded rapidly, with companies opening for business in all major markets worldwide. From 2005 to 2010, the market reached saturation and stabilized.
Then, from 2010 to 2020, the market began to aggressively consolidate. This has created both serious threats and unique opportunities within the industry.
Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation. There are also emerging opportunities for the industry, such as accelerated regulatory pathways for cell therapies in leading healthcare markets worldwide and expanding applications for cell-based therapies. In particular, MSCs from cord tissue (and other sources) are showing intriguing promise in the treatment and management of COVID-19.
Cord Blood Industry Trends
Within recent years, new themes have been impacting the industry, including the pairing of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including umbilical cord tissue storage, placental blood and tissue, amniotic fluid and tissue, and dental pulp. Cord blood banks are also investigating means of becoming integrated therapeutic companies. With hundreds of companies offering cord blood banking services worldwide, maturation of the market means that each company is fighting harder for market share.
Growing numbers of investors are also entering the marketplace, with M&A activity accelerating in the U.S. and abroad. Holding companies are emerging as a global theme, allowing for increased operational efficiency and economy of scale. Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that will control nearly 270,000 stem cell units by the end of 2020. It now owns a half dozen cord blood banks, as well as a dental stem cell storage company.
Globally, networks of cord blood banks have become commonplace, with Sanpower Group establishing its dominance in Asia. Although Sanpower has been quiet about its operations, it holds 4 licenses out of only 7 issued provincial-level cord blood bank licenses in China. It has reserved over 900,000 cord blood samples in China, and its reserves amount to over 1.2 million units when Cordlife' reserves within Southeast Asian countries are included. This positions Sanpower Group and it's subsidiary Nanjing Cenbest as the world’s largest cord blood banking operator not only in China and Southeast Asia but in the world.
The number of cord blood banks in Europe has dropped by more than one-third over the past ten years, from approximately 150 to under 100. The industry leaders in this market segment include FamiCord Group, who has executed a dozen M&A transactions, and Vita34, who has executed approximately a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord. FamiCord is now the leading stem cell bank in Europe and one of the largest worldwide.
Cord Blood Expansion Technologies
Because cord blood utilization is largely limited to use in pediatric patients, growing investment is flowing into ex vivo cord blood expansion technologies. If successful, this technology could greatly expand the market potential for cord blood, encouraging its use within new markets, such as regenerative medicine, aging, and augmented immunity.
Key strategies being explored for this purpose include:
- Nicotinamide-mediated (NAM) expansion
- Notch ligand
- Enforced fucosylation
Currently, Gamida Cell, Nohla Therapeutics, Excellthera, and Magenta Therapeutics have ex vivo cord blood expansion products proceeding through clinical trials. Growing numbers of investors have also entered the cord blood banking marketplace, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC, and Excalibur.
Cord Blood Banking by Region
Within the United States, most of the market share is controlled by three major players: Cord Blood Registry (CBR), Cryo-Cell, and ViaCord. CBR has been traded twice, once in 2015 to AMAG Pharmaceuticals for $700 million and again in 2018 to GI Partners for $530 million. CBR also bought Natera's Evercord Cord Blood Banking business in September 2019. In total, CBR controls over 900,000 cord blood and tissue samples, making it one of the largest cord blood banks worldwide.
In China, the government controls the industry by authorizing only one cord blood bank to operate within each province, and official government support, authorization, and permits are required. Importantly, the Chinese government announced in late 2019 that it will be issuing new licenses for the first time, expanding from the current 7 licensed regions for cord blood banking to up to 19 regions, including Beijing.
In Italy and France, it is illegal to privately store one's cord blood, which has fully eliminated the potential for a private market to exist within the region. In Ecuador, the government created the first public cord blood bank and instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This created a crisis for private banks, forcing most out of business.
Recently, India's Central Drugs Standard Control Organization (CDSCO) restricted commercial banking of stem cells from most biological materials, including cord tissue, placenta, and dental pulp stem cells - leaving only umbilical cord blood banking as “permitted and licensed” within the country.
While market factors vary by geography, it is crucial to have a global understanding of the industry, because research advances, clinical trial findings, and technology advances do not know international boundaries. The cord blood market is global in nature and understanding dynamics within your region is not sufficient for making strategic, informed, and profitable decisions.
Highlights of the Report
This report presents the number of cord blood units stored in inventory by the largest cord blood banks worldwide and the number of cord blood units (CBUs) released by registries across the world for hematopoietic stem cell (HSC) transplantation. Although cord blood is now used to treat more than 80 different diseases, this number could substantially expand if applications related to regenerative medicine start receiving approvals in major healthcare markets worldwide.
Overall, the report provides the reader with the following details and answers the following questions:
1. Number of cord blood units cryopreserved in public and private cord blood banks globally
2. Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells
3. Utilization of cord blood cells in clinical trials for developing regenerative medicines
4. The decline of the utilization of cord blood cells in HSC transplantations since 2005
5. Emerging technologies to influence the financial sustainability of public cord blood banks
6. The future scope for companion products from cord blood
7. The changing landscape of cord blood cell banking market
8. Extension of services by cord blood banks
9. Types of cord blood banks
10. The economic model of public cord blood banks
11. Cost analysis for public cord blood banks
12. The economic model of private cord blood banks
13. Cost analysis for private cord blood banks
14. Profit margins for private cord blood banks
15. Pricing for processing and storage in private banks
16. Rate per cord blood unit in the U.S. and Europe
17. Indications for the use of cord blood-derived HSCs for transplantations
18. Diseases targeted by cord blood-derived MSCs in regenerative medicine
19. Cord blood processing technologies
20. Number of clinical trials, number of published scientific papers and NIH funding for cord blood research
21. Transplantation data from different cord blood registries
Key questions answered in this report are:
1. What are the strategies being considered for improving the financial stability of public cord blood banks?
2. What are the companion products proposed to be developed from cord blood?
3. How much is being spent on processing and storing a unit of cord blood?
4. How much does a unit of cryopreserved cord blood unit fetch on release?
5. Why do most public cord blood banks incur a loss?
6. What is the net profit margin for a private cord blood bank?
7. What are the prices for processing and storage of cord blood in private cord blood banks?
8. What are the rates per cord blood units in the U.S. and Europe?
9. What are the revenues from cord blood sales for major cord blood banks?
10. Which are the different accreditation systems for cord blood banks?
11. What are the comparative merits of the various cord blood processing technologies?
12. What is to be done to increase the rate of utilization of cord blood cells in transplantations?
13. Which TNC counts are preferred for transplantation?
14. What is the number of registered clinical trials using cord blood and cord tissue?
15. How many clinical trials are involved in studying the expansion of cord blood cells in the laboratory?
16. How many matching and mismatching transplantations using cord blood units are performed on an annual basis?
17. What is the share of cord blood cells used for transplantation from 2000 to 2020?
18. What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?
19. Which are the top ten countries for donating cord blood?
20. What are the diseases targeted by cord blood-derived MSCs within clinical trials?
1. REPORT OVERVIEW
1.1 Statement of the Report
1.2 Executive Summary
1.3.1 Cord Blood: An Alternative Source for HPSCs
1.3.2 Utilization of Cord Blood Cells in Clinical Trials
1.3.3 The Struggle of Cord Blood Banks
1.3.4 Emerging Technologies to Influence Financial Sustainability of Banks
22.214.171.124 Other Opportunities to Improve Financial Stability
126.96.36.199 Scope for Companion Products
1.3.5 Changing Landscape of Cord Blood Cell Banking Market
1.3.6 Extension of Services by Cord Blood Banks
2. CORD BLOOD & CORD BLOOD BANKING: AN OVERVIEW
2.1 Cord Blood Banking (Stem Cell Banking)
2.1.1 Public Cord Blood Banks
188.8.131.52 Economic Model of Public Cord Blood Banks
184.108.40.206 Cost Analysis for Public Banks
220.127.116.11 Relationship between Costs and Release Rates
2.1.2 Private Cord Blood Banks
18.104.22.168 Cost Analysis for Private Cord Blood Banks
22.214.171.124 Economic Model of Private Banks
2.1.3 Hybrid Cord Blood Banks
2.2 Globally Known Cord Blood Banks
2.2.1 Comparing Cord Blood Banks
2.2.2 Cord Blood Banks in the U.S.
2.2.3 Proportion of Public, Private and Hybrid Banks
2.3 Percent Share of Parents of Newborns Storing Cord Blood by Country/Region
2.4 Pricing for Processing and Storage in Commercial Banks
2.4.1 Rate per Cord Blood Unit in the U.S. and Europe
2.5 Cord Blood Revenues for Major Cord Blood Banks
3. CORD BLOOD BANK ACCREDITATIONS
3.1 American Association of Blood Banks (AABB)
3.2 Foundation for the Accreditation of Cellular Therapy (FACT)
3.3 FDA Registration
3.4 FDA Biologics License Application (BLA) License
3.5 Investigational New Drug (IND) for Cord Blood
3.6 Human Tissue Authority (HTA)
3.7 Therapeutic Goods Act (TGA) in Australia
3.8 International NetCord Foundation
3.9 AABB Accredited Cord Blood Facilities
3.10 FACT Accreditation for Cord Blood Banks
4. APPLICATIONS OF CORD BLOOD CELLS
4.1 Hematopoietic Stem Cell Transplantations with Cord Blood Cells
4.2 Cord Cells in Regenerative Medicine
5. CORD BLOOD PROCESSING TECHNOLOGIES
5.1 The Process of Separation
5.1.2 Advantages of PrepaCyte-CB
5.1.3 Treatment Outcomes with PrepaCyte-CB
5.1.4 Hetastarch (HES)
5.1.5 AutoXpress (AXP)
5.1.7 Plasma Depletion Method (MaxCell Process)
5.1.8 Density Gradient Method
5.2 Comparative Merits of Different Processing Methods
5.2.1 Early Stage HSC Recovery by Technologies
5.2.2 Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood
5.2.3 Late Stage Recovery of HSCs from Cord Blood
5.3 HSC (CD45+) Recovery
5.4 Days to Neutrophil Engraftment by Technology
5.5 Anticoagulants used in Cord Blood Processing
5.5.1 Type of Anticoagulant and Cell Recovery Volume
5.5.2 Percent Cell Recovery by Sample Size
5.5.3 TNC Viability by Time Taken for Transport and Type of Anticoagulant
5.6 Cryopreservation of Cord Blood Cells
5.7 Bioprocessing of Umbilical Cord Tissue (UCT)
5.8 A Proposal to Improve the Utilization Rate of Banked Cord Blood
6. CORD BLOOD CLINICAL TRIALS, SCIENTIFIC PUBLICATIONS & NIH FUNDING
6.1 Cord Blood Cells for Research
6.2 Cord Blood Cells for Clinical Trials
6.2.1 Number of Clinical Trials involving Cord Blood Cells
6.2.2 Number of Clinical Trials using Cord Blood Cells by Geography
6.2.3 Number of Clinical Trials by Study Type
6.2.4 Number of Clinical Trials by Study Phase
6.2.5 Number of Clinical Trials by Funder Type
6.2.6 Clinical Trials Addressing Indications in Children
6.2.7 Select Three Clinical Trials Involving Children
126.96.36.199 Sensorineural Hearing Loss (NCT02038972)
188.8.131.52 Autism Spectrum (NCT02847182)
184.108.40.206 Cerebral Palsy (NCT01147653)
6.2.8 Clinical Trials for Neurological Diseases using Cord Blood and Cord Tissue
6.2.9 UCB for Diabetes
6.2.10 UCB in Cardiovascular Clinical Trials
6.2.11 Cord Blood Cells for Auto-Immune Diseases in Clinical Trials
6.2.12 Cord Tissue Cells for Orthopedic Disorders in Clinical Trials
6.2.13 Cord Blood Cells for Other Indications in Clinical Trials
6.3 Major Diseases Addressed by Cord Blood Cells in Clinical Trials
6.4 Clinical Trials using Cord Tissue-Derived MSCs
6.5 Ongoing Clinical Trials using Cord Tissue
6.5.1 Cord Tissue-Based Clinical Trials by Geography
6.5.2 Cord Tissue-Based Clinical Trials by Phase
6.5.3 Cord Tissue-Based Clinical Trials by Sponsor Types
6.5.4 Companies Sponsoring in Trials using Cord Tissue-Derived MSCs
6.6 Wharton’s Jelly-Derived MSCs in Clinical Trials
6.6.1 Wharton’s Jelly-Based Clinical Trials by Phase
6.6.2 Companies Sponsoring Wharton’s Jelly-Based Clinical Trials
6.7 Clinical Trials Involving Cord Blood Expansion Studies
6.7.1 Safe and Feasible Expansion Protocols
6.7.2 List of Clinical Trials involved in the Expansion of Cord Blood HSCs
6.7.3 Expansion Technologies
6.8 Scientific Publications on Cord Blood
6.9 Scientific Publications on Cord Tissue
6.10 Scientific Publications on Wharton’s Jelly-Derived MSCs
6.11 Published Scientific Papers on Cord Blood Cell Expansion
6.12 NIH Funding for Cord Blood Research
7. PARENT’S AWARENESS AND ATTITUDE TOWARDS CORD BLOOD BANKING
7.1 Undecided Expectant Parents
7.2 The Familiar Cord Blood Banks Known by the Expectant Parents
7.3 Factors Influencing the Choice of a Cord Blood Bank
8. CORD BLOOD: AS A TRANSPLANTATION MEDICINE
8.1 Comparisons of Cord Blood to other Allograft Sources
8.1.1 Major Indications for HCTs in the U.S.
8.1.2 Trend in Allogeneic HCT in the U.S. by Recipient Age
8.1.3 Trends in Autologous HCT in the U.S. by Recipient Age
8.2 HCTs by Cell Source in Adult Patients
8.2.1 Transplants by Cell Source in Pediatric Patients
8.3 Allogeneic HCTs by Cell Source
8.3.1 Unrelated Donor Allogeneic HCTs in Patients <18 Years
8.4 Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity
8.4.1 Likelihood of Finding an Unrelated Cord Blood Unit for Patients <20 Years
8.5 Odds of using a Baby’s Cord Blood
8.6 Cord Blood Utilization Trends
8.7 Number of Cord Blood Donors Worldwide
8.7.1 Number of CBUs Stored Worldwide
8.7.2 Cord Blood Donors by Geography
220.127.116.11 Cord Blood Units Stored in Different Geographies
18.104.22.168 Number of Donors by HLA Typing
8.7.3 Searches Made by Transplant Patients for Donors/CBUs
8.7.4 Types of CBU Shipments (Single/Double/Multi)
8.7.5 TNC Count of CBUs Shipped for Children and Adult Patients
8.7.6 Shipment of Multiple CBUs
8.7.7 Percent Supply of CBUs for National and International Patients
8.7.8 Decreasing Number of CBU Utilization
8.8 Top Ten Countries in Cord Blood Donation
8.8.1 HLA Typed CBUs by Continent
8.8.2 Percentage TNC of Banked CBUs
8.8.3 Total Number of CBUs, HLA-Typed Units by Country
8.9 Cord Blood Export/Import by the E.U. Member States
8.9.1 Number of Donors and CBUs in Europe
8.9.2 Number of Exports/Imports of CBUs in E.U.
8.10 Global Exchange of Cord Blood Units
9. CORD BLOOD CELLS AS THERAPEUTIC CELL PRODUCTS IN CELL THERAPY
9.1 MSCs from Cord Blood and Cord Tissue
9.1.1 Potential Neurological Applications of Cord Blood-Derived Cells
9.1.2 Cord Tissue-Derived MSCs for Therapeutic use
22.214.171.124 Indications Targeted by UCT-MSCs in Clinical Trials
9.2 Current Consumption of Cord Blood Units by Clinical Trials
9.3 Select Cord Blood Stem Cell Treatments in Clinical Trials
9.3.1 Acquired Hearing Loss (NCT02038972)
9.3.2 Autism (NCT02847182)
9.3.3 Cerebral Palsy (NCT03087110)
9.3.4 Hypoplastic Left Heart Syndrome (NCT01856049)
9.3.5 Type 1 Diabetes (NCT00989547)
9.3.6 Psoriasis (NCT03765957)
9.3.7 Parkinson’s Disease (NCT03550183)
9.3.8 Signs of Aging (NCT04174898)
9.3.9 Stroke (NCT02433509)
9.3.10 Traumatic Brain Injury (NCT01451528)
10. MARKET ANALYSIS
10.1 Public vs. Private Cord Blood Banking Market
10.2 Cord Blood Banking Market by Indication
11. PROFILES OF SELECT CORD BLOOD BANKS
11.1.1 Whole Blood
11.1.3 Mobilized Leukopak
11.1.4 Bone Marrow
11.1.5 Cord Blood
11.2 AlphaCord LLC
11.2.1 NextGen Collection System
11.3 Americord Registry, Inc.
11.3.1 Cord Blood 2.0
11.3.2 Cord Tissue
11.3.3 Placental Tissue 2.0
11.4 Be The Match
11.4.1 Hub of Transplant Network
11.4.2 Partners of Be The Match
11.4.3 Allogeneic Cell Sources in Be The Match Registry
11.4.4 Likelihood of a Matched Donor on Be The Match by Ethnic Background
11.5 Biocell Center Corporation
11.5.1 Chorionic villi after Delivery
11.5.2 Amniotic Fluid and Chorionic Villi during Pregnancy
11.6 BioEden Group, Inc.
11.6.1 Differences between Tooth Cells and Umbilical Cord Cells
11.7 Biovault Family
11.7.1 Personalized Cord Blood Processing
11.8 Cell Care
11.9 Cells4Life Group, LLP
11.9.1 Cells4Life’s pricing
11.9.2 TotiCyte Technology
11.9.3 Cord Blood Releases
11.11 Center for International Blood and Marrow Transplant Research (CIBMTR)
11.11.1 Global Collaboration
11.11.2 Scientific Working Committees
11.11.3 Medicare Clinical Trials and Studies
11.11.4 Cellular Therapy
11.12 Crio-Cell International, Inc.
11.12.1 Advanced Collection Kit
11.12.3 Crio-Cell International’s Pricing
11.12.4 Revenue for Crio-Cell International
11.13 Cord Blood Center Group
11.13.1 Cord Blood Units Released
11.14 Cordlife Group, Ltd.
11.14.1 Cordlife’s Cord Blood Release Track Record
11.15 Core23 Biobank
11.16 Cord Blood Registry (CBR)
11.18.1 Cord Blood Transplantation in Portugal
11.19 Cryo-Cell International, Inc.
11.19.1 Processing Method
11.19.2 Financial Results of the Company
11.21 Cryoviva Biotech Pvt. Ltd
11.22 European Society for Blood and Bone Marrow Transplantation (EBMT)
11.22.1 EBMT Transplant Activity
11.23 FamiCord Group
11.24 GeneCell International
11.25 Global Cord Blood Corporation
11.25.1 The Company’s Business
11.26 HealthBaby Hong Kong
11.26.1 BioArchive System Service Plan
11.26.2 MVE Liquid Nitrogen System
11.28 Insception Lifebank
11.29.1 Placental Banking
11.30 LifeCell International Pvt. Ltd.
11.31 MiracleCord, Inc.
11.32 Maze Cord Blood Laboratories
11.33 New England Cord Blood Bank, Inc.
11.34 New York Cord Blood Center (NYBC)
11.34.2 Laboratory Services
11.35.1 FDA-Approved Sterile Collection Bags
11.35.2 AXP Processing System
11.35.3 BioArchive System
11.36 ReeLabs Pvt. Ltd.
11.37 Smart Cells International, Ltd.
11.38 Stem Cell Cryobank
11.39 StemCyte, Inc.
11.39.1 StemCyte Sponsored Clinical Trials
126.96.36.199 Spinal Cord Injury Phase II
188.8.131.52 Other Trials
11.40 Transcell Biolife
11.42 Vita 34 AG
11.43 World Marrow Donor Association (WMDA)
11.43.1 Search & Match Service
11.44 Worldwide Network for Blood & Marrow Transplantation (WBMT)
INDEX OF FIGURES
Figure 2.1: Profit Margins of Select Private Cord Blood Banks, 2016-2019
Figure 2.2: Cord Blood Banks by Size of Inventory
Figure 2.3: Proportion of Public, Private and Hybrid Banks
Figure 2.4: Percent Share of Parents of Newborns Storing Cord Blood by Country/Region
Figure 2.5: Cord Blood Revenues for Companies, 2016-2019
Figure 3.1: Percent Share of AABB Accredited Cord Blood Facilities by Country
Figure 5.1: Separation of Buffy Layer
Figure 5.2: PrepaCyte-CB
Figure 5.3: Hetastarch (HES)
Figure 5.4: AutoXpress II
Figure 5.5: SEPAX 2
Figure 5.6: Plasma Depletion (PD) Method (MaxCell Process)
Figure 5.7: Density Gradient Separation of Cord Blood
Figure 5.8: Early Stage HSC Recovery from Cord Blood by Technologies
Figure 5.9: Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies
Figure 5.10: Late Stage HSC Recovery from Cord Blood by Technologies
Figure 5.11: HSC (CD45+) Recovery Post Process from Whole Blood by Technologies
Figure 5.12: Days to Neutrophil Engraftment by Technology
Figure 5.13: Difference in TNC Recovery among Anticoagulants
Figure 5.14: Type of Anticoagulant and Cell Recovery Volume
Figure 5.15: Percent Cell Recovery by Sample Size
Figure 5.16: TNC Viability by Time Taken for Transport
Figure 5.17: Difference in Recovery of Viable TNC after Thawing
Figure 5.18: CD34+ Cell Count, CFU and Cell Apoptosis by Cryoprotectants
Figure 5.19: The Number of Stored and Transplanted CB Units in Korea-CORD by TNC
Figure 5.20: Number of Stored and Shipped CB Units and Utilization Rate by TNC Count
Figure 6.1: Number of Clinical Trials as Reported in PubMed.gov from 2000 to 2019
Figure 6.2: Number of Cord Blood Clinical Trials by Geography as of June 2020
Figure 6.3: Number of Cord Blood Clinical Trials by Study Type as of June 2020
Figure 6.4: Number of Cord Blood Clinical Trials by Study Phase as of June 2020
Figure 6.5: Number of Cord Blood Clinical Trials by Funder Type as of June 2020
Figure 6.6: Percent Share of Indications in Children tested in Clinical Trials
Figure 6.7: Percent Share of Diseases in Ongoing Clinical Trials using Cord Blood Cells
Figure 6.8: Percent Share of Diseases in Clinical Trials using MSCs from Cord Tissue
Figure 6.9: Number of Cord Tissue-Based Clinical Trials by Geography as of June 2020
Figure 6.10: Cord Tissue-Based Clinical Trials by Study Phase as of June 2020
Figure 6.11: Cord Tissue-Based Clinical Trials by Funder Type as of June 2020
Figure 6.12: Wharton’s Jelly-Based Clinical Trials by Study Phase as of June 2020
Figure 6.13: Number of Published Scientific Papers on UCB, 2000-June 2020
Figure 6.14: Number of Published Scientific Papers on Cord Tissue, 2000-June 2020
Figure 6.15: Number of Published Scientific Papers on Wharton’s Jelly, 2000-June 2020
Figure 6.16: Number of Published Scientific Papers on Cord Blood Expansion
Figure 7.1: Percent Expectant Parents who have heard about Cord Blood Banking
Figure 7.2: Undecided Expectant Parents about Cord Blood Banking
Figure 7.3: The Familiar Cord Blood Banks Known by the Expectant Parents
Figure 7.4: Factors Influencing the Choice of a Cord Blood Bank
Figure 8.1: Distribution of Cell Sources in HCTs as Reported in Be The Match, 2019
Figure 8.2: Comparisons of Cord Blood to other Allograft Sources
Figure 8.3: Major Indications for HTC in the U.S., 2019
Figure 8.4: Trend in Allogeneic HCT in the U.S. by Recipient Age, 2000-2018
Figure 8.5: Trends in Autologous HCT in the U.S. by Recipient Age, 2000-2018
Figure 8.6: Transplants by Cell Source in Adult Patients, 2010-2019
Figure 8.7: Transplants by Cell Source in Pediatric Patients <18 Years
Figure 8.8: Allogeneic HCTs by Cell Source Facilitated by NMDP/Be The Match
Figure 8.9: Unrelated Donor Allogeneic HCTs in Patients <18 Years/NMDP/Be The Match
Figure 8.10: Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity
Figure 8.11: Likelihood of Finding an Unrelated Cord Blood Unit for Patients <20 Years
Figure 8.12: Cumulative Probability of having a Stem Cell Transplant by Age
Figure 8.13: Cord Blood Utilization Trends
Figure 8.14: Number of UCB Donors Worldwide as Reported by WMDA
Figure 8.15: Number of CBUs Worldwide as Reported by WMDA
Figure 8.16: Number of Umbilical Cord Blood Donors by Geography
Figure 8.17: Number of Cord Blood Units Stored by Geography
Figure 8.18: Percent Shares of all Registered Donors by HLA Typing Level
Figure 8.19: Number of Searches Initiated by National Patients for Donors/CBU/Both
Figure 8.20: Types of CBU Shipments
Figure 8.21: TNC Count of CBUs Provided for Children and Adult Patients - Single
Figure 8.22: TNC Count of CBUs Provided for Children and Adult Patients - Multi
Figure 8.23: Percentage of HPC Products Provided for National and International Patients
Figure 8.25: Top Ten Countries with Number of Donors Listed per 10,000 Inhabitants
Figure 8.26: Percentage of HLA Typed CBUs Banked per Continent
Figure 8.27: Percentage TNC of Banked CBUs
Figure 8.28: Number of Donors per 10,000 Inhabitants by Select E.U. Countries
Figure 8.29: Global CBU Shipments by Geography in 2018
Figure 8.30: Global Shipments of CBUs by Geography in 2012
Figure 9.1: Percent Shares of Indications Targeted by UCB-MSCs in Clinical Trials
Figure 9.2: Percent Share of Clinical Indications using UCT-MSCs
Figure 9.3: Number of UCB Units Released by Cord Blood Registry by Application
Figure 10.1: Global Cord Blood Banking Market Revenue by Geography
Figure 10.2: Percent Share of Global Cord Blood Banking Market Revenue by Geography
Figure 10.3: Percent Share of Global Cord Blood Banking Market, Public vs. Private
Figure 10.4: Percent Share of Cord Blood Banking Market by Indication
Figure 11.1: Growth of CBUs on the Be The Match Registry
Figure 11.2: Growth of CBUs on the Be The Match Registry
Figure 11.3: Number of Unrelated Donor Transplants Facilitated by NMDP/Be The Match
Figure 11.4: Diversity of CBUs in Be The Match Registry
Figure 11.5: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry
Figure 11.6: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
Figure 11.7: Percent Recovery of Viable Cells by TotiCyte Technology
Figure 11.8: Growth in Number of New Transplant Patients Registered with the CIBMTR
Figure 11.9: New Patients per Year Registered with CIBMTR
Figure 11.10: Transplant Patients by Graft Source Registered with CIBMTR
Figure 11.11: Crio-Cell International’s Revenues, 2016-2019
Figure 11.12: Number of Cord Blood Units Stored in CBR and its Competitors
Figure 11.13: Key Figures of Sales Revenues and Gross Profits for Cordlife, 2014-2019
Figure 11.14: Revenue and Gross Profit for GCBC, 2015-2019
Figure 11.15: Percent Share of Units Released by Indication
Figure 11.16: Key Figures of Sales Revenues and Gross Profits for Vita 34, 2014-2019
INDEX OF TABLES
Table 2.1: An Overview of Public Cord Blood Banks
Table 2.2: International Prices of Cord Blood Unit
Table 2.3: Prices of Cord Blood Units in NMDP Banks in the U.S.
Table 2.4: An Overview of Private Cord Blood Banks
Table 2.5: Profit Margins of Select Private Cord Blood Banks, 2016-2019
Table 2.6: An Overview of Hybrid Cord Blood Banks
Table 2.7: A Partial List of Global Private Cord Blood Banks
Table 2.8: Comparison of Three Private Banks
Table 2.9: Partial List of Public, Private and Hybrid Cord Blood Banks in the U.S.
Table 2.10: Pricing for Storage in Commercial Banks
Table 2.11: Rate per Cord Blood Unit in the U.S. & Europe
Table 2.12: Cord Blood Revenues for Major Four Companies, 2016-2019
Table 3.1: AABB Accredited Cord Blood Facilities
Table 3.2: Select FACT Accredited Cord Blood Facilities
Table 4.1: Indications for the Use of UCB-Derived Stem Cells for Transplantation
Table 4.2: Indications for the Use of UCB-Derived Stem Cells for Regenerative Medicine
Table 5.1: Advantages of PrepaCyte-CB
Table 5.2: Treatment Outcomes with PrepaCyte-CB
Table 6.1: U.S. Cord Blood Banks Supplying Cord Blood for Research
Table 6.2: Number of Cord Blood Clinical Trials by Geography as of June 2020
Table 6.3: Number of Cord Blood Clinical Trials by Study Type as of June 2020
Table 6.4: Number of Cord Blood Clinical Trials by Study Phase as of June 2020
Table 6.5: Number of Cord Blood Clinical Trials by Funder Type as of June 2020
Table 6.6: Percent Share of Indications in Children tested in Clinical Trials
Table 6.7: Select Three Clinical Trials involving Children
Table 6.8: Ongoing Clinical Trials using UCB for Neurological Diseases
Table 6.9: Ongoing Clinical Trials using UCB for Diabetes
Table 6.10: Ongoing Clinical Trials using UCB for Cardiovascular Trials
Table 6.11: Ongoing Clinical Trials using UCB for Auto-Immune Diseases
Table 6.12: Ongoing Clinical Trials using UCB for Orthopedic Disorders
Table 6.13: Ongoing Clinical Trials using UCB for Other Indications
Table 6.14: Select Clinical Trials using MSCs from Cord Tissue
Table 6.15: Number of Cord Tissue-Based Clinical Trials by Geography as of June 2020
Table 6.16: Number of Cord Tissue-Based Clinical Trials by Study Phase as of June 2020
Table 6.17: Number of Cord Tissue-Based Clinical Trials by Funder Type as of June 2020
Table 6.18: Select Cord Tissue-Based Clinical Trials by Commercial Entities, 2020
Table 6.19: Wharton’s Jelly-Based Clinical Trials by Phase, 2020
Table 6.20: Wharton’s Jelly-Based Clinical Trials by Commercial Entities, June 2020
Table 6.21: Clinical Trials in Cord Blood-Derived Cell Expansion by Country, 2020
Table 6.22: Clinical Trials of Cell Expansion Studies by Stages in Development, 2020
Table 6.23: List of Clinical Trials involved in the Expansion of Cord Blood HSCs
Table 6.24: Cord Blood Expansion Approaches
Table 6.25: Select NIH Funding for Umbilical Cord Blood Research, 2019-2020
Table 8.1: Comparisons of Cord Blood to other Allograft Sources in Transplantation
Table 8.2: Number of HCTs Performed in the U.S. as reported to CIBMTR by Disease
Table 8.3: Total Number of Cord Blood Donors and Cord Blood Units by Country
Table 8.4: Number of Donors and CBUs by E.U. Country as of December 31, 2018
Table 8.5: Number of Exports/Imports of CBUs in E.U. in 2018
Table 9.1: Select 15 Clinical Trials Using Cord Blood-Derived MSCs as Interventions
Table 9.2: Select Clinical Trials using UCT-MSCs as Interventions
Table 10.1: Global Cord Blood Banking Market Revenue by Geography
Table 11.1: AlphaCord’s pricing
Table 11.2: Cell Care’s pricing for Processing and Storage
Table 11.3: Cells4Life’s pricing for Cord Blood, Cord Tissue, Amnion and Placental Cells
Table 11.4: Cord Blood and Cord Tissue Products Released from Cells4Life
Table 11.5: Distribution of Transplant Patients by Graft Source Registered with CIBMTR
Table 11.6: Distribution of Transplant Patients by Indication Registered with CIBMTR
Table 11.7: Crio-Cell International’s pricing for Processing and Storage
Table 11.8: Crio-Cell International’s Revenues, 2016-2019
Table 11.9: Cord Blood Units Released from Cord Blood Center Group
Table 11.10: Cordlife’s Cord Blood Release Track Record
Table 11.11: Core23 Biobank’s Processing and Storage Fees
Table 11.12: Allogeneic and Autologous Transplantations by Indication Reported in EBMT
Table 11.13: GeneCell Internationals Prepaid Storage Plans
Table 11.14: Selected Financial Data for GCBC, 2015-2019
Table 11.15: Insception Lifebank’s Pricing
Table 11.16: LifeCell International’s pricing
Table 11.17: MiracleCord’s Cost Comparison with Competitors
Table 11.18: Maze Cord Blood Laboratory’s Payment Plans
Table 11.19: Comparison of Pricing of NECBB with others
Table 11.20 Stem Cell Cryobank’s pricing for Processing and Storage
- ABSKKR & Company
- AlphaCord LLC
- AMAG Pharmaceuticals
- Americord Registry, Inc.
- Bay City Capital
- Be The Match
- Biocell Center Corporation
- BioEden Group, Inc.
- Biovault Family
- Cell Care
- Cells4Life Group, LLP
- Center for International Blood and Marrow Transplant Research (CIBMTR)
- Cord Blood Center Group
- Cord Blood Registry (CBR)
- Cordlife Group, Ltd.
- Core23 Biobank
- Crio-Cell International, Inc.
- Cryo-Cell International, Inc.
- Cryoviva Biotech Pvt. Ltd
- European Society for Blood and Bone Marrow Transplantation (EBMT)
- FamiCord Group
- Gamida Cell
- GeneCell International
- GI Partners
- Global Cord Blood Corporation
- GTCR, LLC
- HealthBaby Hong Kong
- Insception Lifebank
- LifeCell International Pvt. Ltd.
- Magenta Therapeutics
- Maze Cord Blood Laboratories
- MiracleCord, Inc.
- Nanjing Cenbest
- New England Cord Blood Bank, Inc.
- New York Cord Blood Center (NYBC)
- Nohla Therapeutics
- ReeLabs Pvt. Ltd.
- Sanpower Group
- Smart Cells International, Ltd.
- Stem Cell Cryobank
- StemCyte, Inc.
- Transcell Biolife
- Vita 34 AG
- World Marrow Donor Association (WMDA)
- Worldwide Network for Blood & Marrow Transplantation (WBMT)
The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.
- Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
- Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
- Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
- Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
- Product Launch Announcements (Trade Journals, Google News)
- Industry Events (Google News, Google Alerts, Press Releases)
- Company News (SEC Filings, Investor Publications, Historical Performance)
- Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
- Interviews with Stem Cell Industry Leaders
Research & Analysis Methodologies
The publisher employs the following techniques for deriving its market research:
- Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
- Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
- Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
- Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
- Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
- Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
- Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).